An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of ...